Published Studies Related to Tolterodine Extended Release
Well-designed clinical trials related to Tolterodine Extended Release
Comparison of fesoterodine and tolterodine extended release for the treatment of
overactive bladder: a head-to-head placebo-controlled trial. [2010]
Tolterodine extended release is well tolerated in older subjects. [2009]
Effect of tolterodine on gastrointestinal transit and bowel habits in healthy
subjects. [2008]
The clinical efficacy of tolterodine extended-release is maintained for 24 h in
patients with overactive bladder. [2007]
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms
and overactive bladder: a randomized controlled trial. [2006]
Efficacy and tolerability of tolterodine extended-release in continent patients
with overactive bladder and nocturia. [2006]
Efficacy and tolerability of tolterodine extended-release in men with overactive
bladder and urgency urinary incontinence. [2006]
Comparison of dry mouth in women treated with extended-release formulations of
oxybutynin or tolterodine for overactive bladder. [2005]
Extended-release formulations of oxybutynin and tolterodine exhibit similar
central nervous system tolerability profiles: a subanalysis of data from the
OPERA trial. [2005]
Long-term safety, tolerability and efficacy of extended-release tolterodine in
the treatment of overactive bladder in Japanese patients. [2005]
Tolterodine treatment for children with symptoms of urinary urge incontinence
suggestive of detrusor overactivity: results from 2 randomized, placebo
controlled trials. [2005]
A comparison of extended-release oxybutynin and tolterodine for treatment of
overactive bladder in women. [2004]
Health-related quality of life of Japanese patients with overactive bladder
treated with extended-release tolterodine or immediate-release oxybutynin: a
randomized, placebo-controlled trial. [2004]
Clinical efficacy and tolerability of extended-release tolterodine and
immediate-release oxybutynin in Japanese and Korean patients with an overactive
bladder: a randomized, placebo-controlled trial. [2003]
Reduced perception of urgency in treatment of overactive bladder with
extended-release tolterodine. [2003]
Prospective, randomized, double-blind study of the efficacy and tolerability of
the extended-release formulations of oxybutynin and tolterodine for overactive
bladder: results of the OPERA trial. [2003]
A new once-daily formulation of tolterodine provides superior efficacy and is
well tolerated in women with overactive bladder. [2003]
Health-related quality of life of patients receiving extended-release tolterodine
for overactive bladder. [2002]
Long-term safety, tolerability and efficacy of extended-release tolterodine in
the treatment of overactive bladder. [2002]
Efficacy, safety, and tolerability of extended-release once-daily tolterodine
treatment for overactive bladder in older versus younger patients. [2002]
A comparison of the effects on saliva output of oxybutynin chloride and
tolterodine tartrate. [2001]
Prospective randomized controlled trial of extended-release oxybutynin chloride
and tolterodine tartrate in the treatment of overactive bladder: results of the
OBJECT Study. [2001]
Tolterodine once-daily: superior efficacy and tolerability in the treatment of
the overactive bladder. [2001]
Well-designed clinical trials possibly related to Tolterodine Extended Release
Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539
for nonneurogenic overactive bladder syndrome. [2014]
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
Efficacy and tolerability of fesoterodine in women with overactive bladder. [2009]
Impact of fesoterodine on quality of life: pooled data from two randomized
trials. [2008]
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in
subjects with overactive bladder. [2007]
Safety and tolerability of extended-release oxybutynin once daily in urinary
incontinence: combined results from two phase 4 controlled clinical trials. [2007]
Solifenacin in overactive bladder syndrome. [2005]
Oxybutynin extended-release: a review of its use in the management of overactive
bladder. [2004]
Other research related to Tolterodine Extended Release
Combination of sacral neuromodulation and tolterodine for treatment of idiopathic
overactive bladder in women: a clinical trial. [2014]
Efficacy and safety of combined therapy with tamsulosin and tolterodine in female
patients with a maximal flow rate less than 12 ml/s. [2011]
Other possibly related research studies
Posterior tibial nerve stimulation for treating neurologic bladder in women: a
randomized clinical trial. [2014]
|
